Compare PEB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | 2015 |
| Metric | PEB | NVCR |
|---|---|---|
| Price | $18.33 | $17.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $13.30 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,544,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $2.25 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.53 | ★ 8.28 |
| 52 Week Low | $9.99 | $9.82 |
| 52 Week High | $19.93 | $21.45 |
| Indicator | PEB | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 57.62 |
| Support Level | $18.35 | $14.84 |
| Resistance Level | $19.73 | $18.41 |
| Average True Range (ATR) | 0.48 | 0.77 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 69.78 | 78.63 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.